secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001789769-24-000034
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio reports Q4 net loss $1.99/share; ends ITIL-306 trial, closes UK facility
--------------------------------------------------------------------------------

- Cash and investments of $175.0M as of Dec 31, 2023, down from $260.9M a year earlier; runway expected beyond 2026.
- Q4 2023 net loss $1.99/share (GAAP), $1.26/share non-GAAP; full year net loss $24.00/share.
- R&D expenses fell to $2.0M in Q4 2023 from $20.7M in Q4 2022; restructuring/impairment charges totaled $72.0M for the year.
- Strategic collaboration announced for FRα-CoStAR TIL in NSCLC in China; ITIL-306 clinical trial stopped.
- Closed UK manufacturing facility; management exploring in-licensing/acquisition of novel therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000034/0001789769-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000034/til-20240321.htm
  HTML page:      https://secwatch.observer/filing/0001789769-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer